Read more about Intas Pharma files draft prospectus for IPO on Business Standard. Drug maker Intas Pharmaceuticals today said it has filed. Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with Securities and Exchange Board of India (SEBI) for an initial public. Intas Pharma DRHP News: Latest and Breaking News on Intas Pharma DRHP. Explore Intas Pharma DRHP profile at Times of India for photos, videos and latest .
|Published (Last):||5 November 2004|
|PDF File Size:||5.58 Mb|
|ePub File Size:||3.54 Mb|
|Price:||Free* [*Free Regsitration Required]|
In what could further strengthen its business in European and non-European countries, Ahmedabad based Intas Pharmaceuticals Ltd has acquired hospital business of Combino Pharm in Spain and Portugal for an undisclosed sum.
Intas Pharma eyes hospitals in Europe, US. Intas Pharma buys Spanish company’s hospital business.
Intas Pharma DRHP: Latest News, Videos and Photos of Intas Pharma DRHP | Times of India
The promoters of the company are Mr. At present, domestic companies are marketing their products only in emerging markets, but the largest and most lucrative market for all pharmaceuticals — the US — is the next stop. Nimish Hasmukhbhai Chudgar, Dr. MCI to probe foreign jaunts by MP doctors. Hyderabad-based pharma giant Aurobindo snaps up Portuguese co for Rs crore.
It has also extended its presence into other therapy areas such as gynecology, infertility, arthritis and the respiratory.
Intas Pharmaceuticals files DRHP for IPO
New Delhi, May 26 RPG Life Sciences has sold its Gujarat-based biotechnology unit to Intas Pharmaceuticals for Rs 25 crore to focus on core areas of business and improve long-term competitiveness in a rapidly changing market. It is currently ranked as the srhp largest pharmaceutical company in the country with a 2.
Subscribe to BioSpectrum India. Mon, Dec 31, Updated Rahul Gandhi listed as ‘non-Hindu’. Intas Pharma files for an IPO. The company is present in various major therapy areas such as those relating to neurology, psychiatry, cardiology, pain management, gastroenterology, diabetology, nephrology, urology, anti-infective therapy, dermatology, gynecology, respiratory system, oncology, critical care and ophthalmology with a inttas focus on chronic therapy areas relating to neurology, psychiatry, cardiology and diabetology.
Web Interface Conceived and Powered By: The IPO will be made through a public issue of equity shares of face value of Rs. Intas Pharma merges group companies, subsidiaries. Intas to buy Teva’s UK, Ireland assets for mn pounds.
Desi pharma companies top in biosimilars globally. Sun Pharma in early talks to buy Intas Pharma. The Ahmedabad-based company is considering licensing agreements with hospital-based businesses in these markets. Monday, 31 December Dthp Council of India MCI will investigate a complaint against 11 doctors from Madhya Pradesh who are charged with accepting foreign jaunts sponsored by pharmaceutical company.
Email Enter a valid email address. Intas Pharma launches first etanercept biosimilar. Drug-maker Intas Pharmaceuticals has merged all its group companies and subsidiaries over concerns about imtas profits. Visit Our Digital Magazine: Intas Pharma is a vertically integrated Indian pharmaceutical company with global operations, engaged in the development, manufacture and marketing of pharmaceutical formulation.
Its products are marketed in over 60 countries, either directly, through its subsidiaries or indirectly, through supply, distribution and other arrangements with various leading global intass companies.
Sources said the group has started a process to sell drug discovery services company Advinus Therapeutics, drawing interest from private equity funds Kedaara Capital and True North as intaw as from strategic players, GVK Biosciences and Lambda, a unit of Intas Pharma. Please note that comments are moderated and are generally published if they are on-topic and not abusive.
From around the Web. Please click here to Sign-in or Sign-up. All rights reserved Disclaimer. Chandra kicks off divestment plan. We will get in touch with you shortly.